Login to Your Account

Financings NEWS

SAN FRANCISCO – For the first time since emerging from stealth mode last year, 2015 startup Kiniksa Pharmaceuticals disclosed its $80 million series A round and introduced the first compound in its pipeline.

Vir Biotechnology Inc., a new enterprise pursuing infectious disease therapies with immunology ideas popularized by cancer fighters, is launching under the leadership of departing Biogen Inc. CEO George Scangos.

Loxo Oncology Inc. is seeking to raise approximately $120 million through an underwritten public offering of 3.87 million common shares priced at $31 apiece, a discount of about 5 percent from Wednesday's close of $32.69 for the company's shares (NASDAQ:LOXO).

More Financings Headlines

Cast Your Vote

Should there be restrictions on the use of gene-editing technology?: